LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Theranos, Inc. (“Theranos” or the “Company”) investors concerning the Company and its officers’ possible violations of federal securities laws.
In 2013, Theranos partnered with Walgreens to offer in-store blood tests at Walgreens locations, as well as marketed Theranos' proprietary finger-prick blood-test technology and its benefits. However, Theranos' technology, efficacy and commercial viability began being questioned by reporters and government regulators as early as 2015. Then in July 2016, Walgreens ceased its partnership with Theranos, federal regulators closed Theranos' labs and barred certain Theranos' officers from operating labs. Theranos did disclose that most of its tests for the past three years were conducted on conventional equipment, and not on Theranos' highly touted proprietary technology.
If you purchased Theranos securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
